| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Mahesh V. Patel
Also a director
President and Chief Executive Officer
|
69 |
Since 1997
29 years
|
Not stated | $986,336 | |
|
Nachiappan Chidambaram
Senior Vice President, Research and Development
|
Not stated |
Since 2022
4 years
|
2007 | $530,904 | |
|
Krista Fogarty
Principal Accounting Officer and Corporate Controller
|
Not stated | Not stated | Not stated | $445,957 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 21, 2026 · updated by the 8-Ks of Aug 3, 2026 and Aug 21, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Richard Dana Ono, Ph.D.
Board chair, Lead independent director
|
73 |
2014
12 years
|
Independent |
Audit Committee · Chair
Compensation Committee
|
None stated | Not stated | |
|
Mahesh V. Patel, Ph.D.
CEO
|
69 |
1997
29 years
|
Not stated | None stated | None stated | Paid as CEO | |
|
John W. Higuchi
|
58 |
2003
23 years
|
Independent | None stated | None stated | $59,024 | |
|
Jill M. Jene, Ph.D., M.B.A.
|
53 |
2022
4 years
|
Independent | None stated | None stated | Not stated | |
|
Michael Grissinger
Joined Aug 3, 2026
|
- | - | Independent |
Compensation Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Assignment and license of cough and cold field intellectual property to Spriaso, with a potential royalty of 20% of Spriaso's net proceeds up to $10 million and an exclusive license granted back to the Company outside the cough and cold field
Services agreement under which the Company provides up to 10% of the services of certain employees to Spriaso; the agreement expired in 2021 but may be extended by written agreement
Loading...
